CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: It would be interesting to study in vitro the impact of blocking the immune checkpoint PD-1 on innate CD8-T cells from healthy donors on their cytotoxic functions, and thereby attempt to reproduce the “PD-1 signature” associated with non-relapsed CML patients.